Literature DB >> 32711250

An effective vaginal gel to deliver CRISPR/Cas9 system encapsulated in poly (β-amino ester) nanoparticles for vaginal gene therapy.

Gang Niu1, Zhuang Jin1, Chong Zhang2, Dan He3, Xueqin Gao4, Chenming Zou2, Wei Zhang2, Jiahui Ding2, Bhudev C Das5, Konstantin Severinov6, Inga Isabel Hitzeroth7, Priya Ranjan Debata8, Xin Ma9, Xun Tian10, Qinglei Gao11, Jun Wu12, Zeshan You1, Rui Tian1, Zifeng Cui1, Weiwen Fan1, Weiling Xie1, Zhaoyue Huang1, Chen Cao10, Wei Xu1, Hongxian Xie13, Hongyan Xu14, Xiongzhi Tang15, Yan Wang16, Zhiying Yu17, Hui Han18, Songwei Tan19, Shuqin Chen20, Zheng Hu21.   

Abstract

BACKGROUND: Gene therapy has held promises for treating specific genetic diseases. However, the key to clinical application depends on effective gene delivery.
METHODS: Using a large animal model, we developed two pharmaceutical formulations for gene delivery in the pigs' vagina, which were made up of poly (β-amino ester) (PBAE)-plasmid polyplex nanoparticles (NPs) based two gel materials, modified montmorillonite (mMMT) and hectorite (HTT).
FINDINGS: By conducting flow cytometry of the cervical cells, we found that PBAE-GFP-NPs-mMMT gel was more efficient than PBAE-GFP-NPs-HTT gel in delivering exogenous DNA intravaginally. Next, we designed specific CRISPR/SpCas9 sgRNAs targeting porcine endogenous retroviruses (PERVs) and evaluated the genome editing efficacy in vivo. We discovered that PERV copy number in vaginal epithelium could be significantly reduced by the local delivery of the PBAE-SpCas9/sgRNA NPs-mMMT gel. Comparable genome editing results were also obtained by high-fidelity version of SpCas9, SpCas9-HF1 and eSpCas9, in the mMMT gel. Further, we confirmed that the expression of topically delivered SpCas9 was limited to the vagina/cervix and did not diffuse to nearby organs, which was relatively safe with low toxicity.
INTERPRETATION: Our data suggested that the PBAE-NPs mMMT vaginal gel is an effective preparation for local gene therapy, yielding insights into novel therapeutic approaches to sexually transmitted disease in the genital tract. FUNDING: This work was supported by the National Science and Technology Major Project of the Ministry of science and technology of China (No. 2018ZX10301402); the National Natural Science Foundation of China (81761148025, 81871473 and 81402158); Guangzhou Science and Technology Programme (No. 201704020093); National Ten Thousand Plan-Young Top Talents of China, Fundamental Research Funds for the Central Universities (17ykzd15 and 19ykyjs07); Three Big Constructions-Supercomputing Application Cultivation Projects sponsored by National Supercomputer Center In Guangzhou; the National Research FFoundation (NRF) South Africa under BRICS Multilateral Joint Call for Proposals; grant 17-54-80078 from the Russian Foundation for Basic Research.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CRISPR/Cas9; Gene therapy; Local delivery; Poly (β-amino ester); Vaginal gel

Mesh:

Substances:

Year:  2020        PMID: 32711250      PMCID: PMC7387785          DOI: 10.1016/j.ebiom.2020.102897

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   8.143


  55 in total

Review 1.  Vaginal gene therapy.

Authors:  Alicia Rodríguez-Gascón; Ana Del Pozo-Rodríguez; Arantxazu Isla; María Angeles Solinís
Journal:  Adv Drug Deliv Rev       Date:  2015-07-17       Impact factor: 15.470

2.  Liposomal delivery system enhances anti-inflammatory properties of curcumin.

Authors:  Purusotam Basnet; Haider Hussain; Ingunn Tho; Natasa Skalko-Basnet
Journal:  J Pharm Sci       Date:  2011-10-11       Impact factor: 3.534

Review 3.  Poly(β-amino ester)-based gene delivery systems: From discovery to therapeutic applications.

Authors:  Rosemeyre A Cordeiro; Arménio Serra; Jorge F J Coelho; Henrique Faneca
Journal:  J Control Release       Date:  2019-08-24       Impact factor: 9.776

Review 4.  Polymer-based nanocarriers for vaginal drug delivery.

Authors:  José das Neves; Rute Nunes; Alexandra Machado; Bruno Sarmento
Journal:  Adv Drug Deliv Rev       Date:  2014-12-27       Impact factor: 15.470

5.  Polymeric Materials for Gene Delivery and DNA Vaccination.

Authors:  David N Nguyen; Jordan J Green; Juliana M Chan; Robert Longer; Daniel G Anderson
Journal:  Adv Mater       Date:  2008-12-04       Impact factor: 30.849

6.  Mapping the genomic landscape of CRISPR-Cas9 cleavage.

Authors:  Peter Cameron; Chris K Fuller; Paul D Donohoue; Brittnee N Jones; Matthew S Thompson; Matthew M Carter; Scott Gradia; Bastien Vidal; Elizabeth Garner; Euan M Slorach; Elaine Lau; Lynda M Banh; Alexandra M Lied; Leslie S Edwards; Alexander H Settle; Daniel Capurso; Victor Llaca; Stéphane Deschamps; Mark Cigan; Joshua K Young; Andrew P May
Journal:  Nat Methods       Date:  2017-05-01       Impact factor: 28.547

7.  Hyperbranched poly(β-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer.

Authors:  Xueqin Gao; Zhuang Jin; Xiangyu Tan; Chong Zhang; Chenming Zou; Wei Zhang; Jiahui Ding; Bhudev C Das; Konstantin Severinov; Inga Isabel Hitzeroth; Priya Ranjan Debata; Dan He; Xin Ma; Xun Tian; Qinglei Gao; Jun Wu; Rui Tian; Zifeng Cui; Weiwen Fan; Zhaoyue Huang; Chen Cao; Yuxian Bao; Songwei Tan; Zheng Hu
Journal:  J Control Release       Date:  2020-02-28       Impact factor: 9.776

8.  Enhanced gene transfection efficiency by low-dose 25 kDa polyethylenimine by the assistance of 1.8 kDa polyethylenimine.

Authors:  Hui Zhang; Zhiyi Chen; Meng Du; Yue Li; Yuhao Chen
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 9.  Gene therapy returns to centre stage.

Authors:  Luigi Naldini
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

Review 10.  The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications.

Authors:  Zheng Hu; Ding Ma
Journal:  Cancer Med       Date:  2018-09-14       Impact factor: 4.452

View more
  4 in total

1.  The comparison of ZFNs, TALENs, and SpCas9 by GUIDE-seq in HPV-targeted gene therapy.

Authors:  Zifeng Cui; Hui Liu; Hongfeng Zhang; Zhaoyue Huang; Rui Tian; Lifang Li; Weiwen Fan; Yili Chen; Lijie Chen; Sen Zhang; Bhudev C Das; Konstantin Severinov; Inga Isabel Hitzeroth; Priya Ranjan Debata; Zhuang Jin; Jiashuo Liu; Zheying Huang; Weiling Xie; Hongxian Xie; Bin Lang; Ji Ma; Haiyan Weng; Xun Tian; Zheng Hu
Journal:  Mol Ther Nucleic Acids       Date:  2021-08-19       Impact factor: 8.886

2.  Co-Delivery of p53 Restored and E7 Targeted Nucleic Acids by Poly (Beta-Amino Ester) Complex Nanoparticles for the Treatment of HPV Related Cervical Lesions.

Authors:  Jinfeng Xiong; Guannan Li; Xinyu Mei; Jiahui Ding; Hui Shen; Da Zhu; Hui Wang
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

3.  FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity.

Authors:  Zifeng Cui; Rui Tian; Zhaoyue Huang; Zhuang Jin; Lifang Li; Jiashuo Liu; Zheying Huang; Hongxian Xie; Dan Liu; Haiyan Mo; Rong Zhou; Bin Lang; Bo Meng; Haiyan Weng; Zheng Hu
Journal:  Nat Commun       Date:  2022-03-17       Impact factor: 14.919

Review 4.  Emerging Bioactive Agent Delivery-Based Regenerative Therapies for Lower Genitourinary Tissues.

Authors:  Lin-Cui Da; Yan Sun; Yun-Hong Lin; Su-Zhu Chen; Gang-Xin Chen; Bei-Hong Zheng; Sheng-Rong Du
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.